Sentences with phrase «new immune checkpoint»

Not exact matches

Investigators have repeatedly touted the drug as a potential lynchpin in immuno - oncology, focusing on an enzyme that suppresses the immune cells Opdivo and a whole new class of PD - 1 / L1 checkpoints are designed to unleash in an attack on cancer cells.

Wrangle and Rubinstein's therapy is a combination of a checkpoint drug, nivolumab, with a new and powerful immune stimulation drug, ALT - 803.

One recent tally found more than 1100 studies combining a popular new class called checkpoint inhibitor drugs, which unleash suppressed immune cells, with other treatments.

Checkpoint inhibitors, which aim to unleash the power of the immune system on tumors, are some of the most impressive new cancer treatments.

A new class of drugs called immune checkpoint inhibitors block molecules on T cells that shut down immune response, freeing the immune system to attack tumors.

Commenting on the two studies, Baas says that finding a good treatment for mesothelioma has been a challenge for many years and has so far led to many disappointments, so there is a need for investigation into new pathways such as the use of immune checkpoint inhibitors that target the PD - 1 / PD - L1 pathway.

«Our results in experimental models of cancer suggest a new therapeutic strategy based on inhibiting the microRNA machinery — or the Let - 7 microRNAs — specifically in the TAMs, which may unleash the power of mainstream immunotherapies, such as immune checkpoint inhibitors.»

ALEXANDRIA, VA, FORT WASHINGTON, PA. — Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer.

«The data presented at AACR provide important new models and mechanistic insights that inform our planned development efforts to evaluate the ability of microbiome therapy to augment immune checkpoint inhibitors,» said David Cook, Ph.D., Chief Scientific Officer and Executive Vice President of Research at Seres.

The data presented provide new insights on the potential mechanism by which Seres» microbiome therapies could improve the outcomes of cancer patients treated with immune checkpoint inhibitors.

In recent years, though, discoveries have led to a new class of drugs called checkpoint inhibitors, which have mobilized the immune system to see and go after cancer.

A Brief Report published recently in the New England Journal of Medicine detailed two cases of patients treated with combination immune checkpoint blockade for metastatic melanoma who developed myositis, early progressive and refractory cardiac electrical instability, and myocarditis.

In an effort to further exploit the potential of Pexa - Vec to activate the immune system to fight cancer, as seen in McDonald's preclinical data, SillaJen recently announced a new clinical trial in collaboration with New York - based Regeneron Inc. to test Pexa - Vec and REGN2810, a PD - 1 checkpoint inhibitor, in combination against renal cell carcinoma, and recently signed a sponsored research agreement with UCSF to enable joint support of parallel preclinical experiments by McDonald's tenew clinical trial in collaboration with New York - based Regeneron Inc. to test Pexa - Vec and REGN2810, a PD - 1 checkpoint inhibitor, in combination against renal cell carcinoma, and recently signed a sponsored research agreement with UCSF to enable joint support of parallel preclinical experiments by McDonald's teNew York - based Regeneron Inc. to test Pexa - Vec and REGN2810, a PD - 1 checkpoint inhibitor, in combination against renal cell carcinoma, and recently signed a sponsored research agreement with UCSF to enable joint support of parallel preclinical experiments by McDonald's team.

Head and neck cancer has one currently approved immunotherapy, the checkpoint inhibitor nivolumab (Opdivo ®) and is one of the major cancer types for which new immune - based cancer treatments are in development.

The laboratory of Linda Bradley, Ph.D., professor at SBP, recently published a paper identifying PSGL - 1, a protein that limits T cell responses to viruses, as a new target for checkpoint inhibition, an approach akin to taking the «brakes» off the immune system.

The combination of the attenuated oncolytic virus talimogene laherparepvec (T - VEC) and the immune checkpoint inhibitor pembrolizumab shows activity and is well tolerated by advanced melanoma patients, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18 — 21 in San Francisco.